trending Market Intelligence /marketintelligence/en/news-insights/trending/EI9wGAeMyZC0QAey1boM5Q2 content esgSubNav
In This List

Teva seeks US FDA approval for migraine treatment

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Teva seeks US FDA approval for migraine treatment

Teva Pharmaceutical Industries Ltd. filed a biologics license application, seeking approval for its migraine treatment fremanezumab from the U.S. Food and Drug Administration.

The submission is supported by the results of two phase 3 trials that involved patients with episodic and chronic migraine. The drug met its primary and secondary endpoints reducing the number of migraine days.

Fremanezumab is a fully humanized monoclonal antibody targeting the calcitonin gene-related peptide ligand, a well-validated target in migraine.